Download PDF
Thromb Haemost 1990; 63(03): 525-526
DOI: 10.1055/s-0038-1645078
Letter to the Editor
Schattauer GmbH Stuttgart

The Effect of Picotamide on Platelet Function in Patients with Myeloproliferative Disorders

Daniela Rafanelli
,
Alberto Grossi
,
Alessandro M Vannucchi
,
Sandro Cinotti
,
Massimo Morfini
,
Pierluigi Rossi Ferrini
Further Information

Publication History

Received: 24 July 1989

Accepted after revision 17 January 1990

Publication Date:
30 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Murphy S. Thrombocytosis and thrombocythemia. In: Clinics in Haematology: Platelet Disorders Harker LA, Zimmerman TS. eds W. B. Saunders Company; London: 1983: 989-1065
  • 2 Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-14
    PubMedGoogle Scholar
  • 3 Grossi A, Rosseti S, Vannucchi AM, Rafanelli D, Rossi FerriniP. Occurrence of haemorragic and thrombotic events in myeloproliferative disorders: a retrospective study of 108 patients. Clin Lab Haematol 1988; 10: 167-75
    CrossrefPubMedGoogle Scholar
  • 4 Boughton BJ, Corbett WE N, Ginsburg AD. Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function. J Clin Pathol 1977; 30: 228-34
    CrossrefPubMedGoogle Scholar
  • 5 Pareti FI, Gugliotta L, Mannucci L, Guarini A, Mannucci PM. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemostas 1982; 47: 84-9
    PubMedGoogle Scholar
  • 6 Grossi A, Vannucchi AM, Rafanelli D, Filimberti E, Rossi Ferrini P. Beta-thromboglobulin content in megakaryocytes of patients with myeloproliferative diseases. Thromb Res 1986; 43: 367-74
    CrossrefPubMedGoogle Scholar
  • 7 Kessler CM, Harvey GK, Havlik RJ. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 1982; 50: 157-67
    CrossrefPubMedGoogle Scholar
  • 8 Tartaglia AP, Goldberg JD, Silverstein MN. et al Aspirin and Persantine does not prevent thrombotic complications in patients with polycythemia vera treated with phlebotomy. Blood 1981; (Suppl. 58) 240 A
    PubMedGoogle Scholar
  • 9 Viero P, Cortelazzo S, Bassan R, Barbui T. Effect of aspirin on platelet 5-hydroxytriptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative disorders. Thromb Haemostas 1982; 48: 125-6
    PubMedGoogle Scholar
  • 10 Violi F, Ghiselli A, Iuliano L, Pratico’ D, Alessandri C, Balsano F. Inhibition by Picotamide of thromboxane production in vitro and ex-vivo. Eur J Clin Pharmacol 1988; 33: 599-602
    CrossrefPubMedGoogle Scholar
  • 11 Deckmyn BO H, Gresele P, Van Houtte E, Nenci GG, Vermylen J. Synergism of a thromboxane (Tx) synthetase inhibitor (TSI) and a Tx receptor antagonist (TRA) in reducing platelet activation. Thromb Haemostas 1985; 54: 114
    PubMedGoogle Scholar
  • 12 Martinez J, Shapiro SS, Holburn R. Metabolism of human prothrombin and fibrinogen in patients with thrombocytosis secondary to myeloproliferative states. Blood 1973; 42: 35-46
    PubMedGoogle Scholar